SG10201811128RA - Ezh2 inhibitors for treating lymphoma - Google Patents
Ezh2 inhibitors for treating lymphomaInfo
- Publication number
- SG10201811128RA SG10201811128RA SG10201811128RA SG10201811128RA SG10201811128RA SG 10201811128R A SG10201811128R A SG 10201811128RA SG 10201811128R A SG10201811128R A SG 10201811128RA SG 10201811128R A SG10201811128R A SG 10201811128RA SG 10201811128R A SG10201811128R A SG 10201811128RA
- Authority
- SG
- Singapore
- Prior art keywords
- ezh2 inhibitors
- treating
- ezh2
- lymphoma
- treating lymphoma
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 5
- 206010025323 Lymphomas Diseases 0.000 title abstract 2
- 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 abstract 4
- 101000882127 Homo sapiens Histone-lysine N-methyltransferase EZH2 Proteins 0.000 abstract 4
- NSQSAUGJQHDYNO-UHFFFAOYSA-N n-[(4,6-dimethyl-2-oxo-1h-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide Chemical compound C=1C(C=2C=CC(CN3CCOCC3)=CC=2)=CC(C(=O)NCC=2C(NC(C)=CC=2C)=O)=C(C)C=1N(CC)C1CCOCC1 NSQSAUGJQHDYNO-UHFFFAOYSA-N 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229950004774 tazemetostat Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
EZH2 INHIBITORS FOR TREATING LYMPHOMA The present invention relates to methods of treating cancer by administering an EZH2 inhibitor or a pharmaceutical composition thereof to the subject in need thereof. The present claims define methods for treating specific subtypes of non-Hodgkin's lymphoma comprising the administration to a subject of EZH2 inhibitors. Preferred EZH2 inhibitors include tazemetostat (EPZ-6438 E7438) and other compounds. Dosage amounts and regimes are also defined. [Figure 7]
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462013522P | 2014-06-17 | 2014-06-17 | |
| US201462036265P | 2014-08-12 | 2014-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201811128RA true SG10201811128RA (en) | 2019-01-30 |
Family
ID=54936086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201811128RA SG10201811128RA (en) | 2014-06-17 | 2015-06-17 | Ezh2 inhibitors for treating lymphoma |
| SG11201610273VA SG11201610273VA (en) | 2014-06-17 | 2015-06-17 | Ezh2 inhibitors for treating lymphoma |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201610273VA SG11201610273VA (en) | 2014-06-17 | 2015-06-17 | Ezh2 inhibitors for treating lymphoma |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US10166238B2 (en) |
| EP (2) | EP4252851A3 (en) |
| JP (1) | JP6779793B2 (en) |
| KR (2) | KR20230031963A (en) |
| CN (2) | CN106999498B (en) |
| AU (3) | AU2015277139A1 (en) |
| BR (1) | BR112016029492A2 (en) |
| CA (1) | CA2952074C (en) |
| DK (1) | DK3157527T3 (en) |
| EA (1) | EA038337B1 (en) |
| ES (1) | ES2948442T3 (en) |
| FI (1) | FI3157527T3 (en) |
| HU (1) | HUE062158T2 (en) |
| IL (3) | IL309539A (en) |
| LT (1) | LT3157527T (en) |
| MX (2) | MX2016016744A (en) |
| PL (1) | PL3157527T3 (en) |
| PT (1) | PT3157527T (en) |
| SG (2) | SG10201811128RA (en) |
| SI (1) | SI3157527T1 (en) |
| WO (1) | WO2015195848A1 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130102477A1 (en) | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| CN105873592B (en) | 2013-12-06 | 2023-01-31 | Epizyme股份有限公司 | Combination therapy for the treatment of cancer |
| PT3157527T (en) * | 2014-06-17 | 2023-06-30 | Eisai R&D Man Co Ltd | Ezh2 inhibitors for treating lymphoma |
| MX2021007003A (en) * | 2014-10-16 | 2022-08-09 | Epizyme Inc | Method for treating cancer. |
| IL296080B2 (en) * | 2014-11-17 | 2023-12-01 | Eisai R&D Man Co Ltd | Method for treating cancer |
| AR102767A1 (en) | 2014-12-05 | 2017-03-22 | Lilly Co Eli | EZH2 INHIBITORS |
| EA201792304A1 (en) | 2015-04-20 | 2018-03-30 | Эпизайм, Инк. | COMBINED THERAPY FOR CANCER TREATMENT |
| EA201890009A1 (en) * | 2015-06-10 | 2018-07-31 | Эпизайм, Инк. | EZH2 INHIBITORS FOR TREATING LYMPHOMA |
| MX2018002344A (en) | 2015-08-24 | 2018-07-06 | Epizyme Inc | Method for treating cancer. |
| TW201718598A (en) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Inhibitors of EZH2 |
| JP2019503391A (en) | 2016-01-29 | 2019-02-07 | エピザイム，インコーポレイティド | Combination therapy to treat cancer |
| AU2017273726B2 (en) | 2016-06-01 | 2023-10-19 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| US11147819B2 (en) | 2016-06-17 | 2021-10-19 | Epizyme, Inc. | EZH2 inhibitors for treating cancer |
| EP3570839B1 (en) * | 2017-01-20 | 2020-12-02 | Constellation Pharmaceuticals, Inc. | Solid dispersions of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide |
| US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| EP3630080A4 (en) | 2017-06-02 | 2021-03-10 | Epizyme, Inc. | Use of ezh2 inhibitors for treating cancer |
| US20210161883A1 (en) * | 2017-07-10 | 2021-06-03 | Constellation Pharmaceuticals, Inc. | Ezh2 inhibitor-induced gene expression |
| JP7399079B2 (en) | 2017-09-05 | 2023-12-15 | エピザイム，インコーポレイティド | Combination therapy to treat cancer |
| CN110950834A (en) * | 2019-11-26 | 2020-04-03 | 济南大学 | Identification and evaluation of novel EED-EZH2 interaction small molecule inhibitors |
| CN110960525A (en) * | 2019-11-26 | 2020-04-07 | 济南大学 | Identification and evaluation of novel EED-EZH2 interaction inhibitors |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
| RU2618475C2 (en) | 2010-09-10 | 2017-05-03 | Эпизайм, Инк. | Human ezh2 inhibitors and methods of application thereof |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| EP3323820B1 (en) | 2011-02-28 | 2023-05-10 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| TW201733984A (en) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | Substituted benzene compounds |
| JO3438B1 (en) | 2011-04-13 | 2019-10-20 | Epizyme Inc | Aryl- or heteroaryl-substituted benzene compounds |
| BR112014007603A2 (en) | 2011-09-30 | 2017-06-13 | Glaxosmithkline Llc | cancer treatment methods |
| TR201904660T4 (en) | 2012-03-12 | 2019-05-21 | Epizyme Inc | Human EZH2 inhibitors and methods of use. |
| IL289300B1 (en) | 2012-04-13 | 2024-01-01 | Epizyme Inc | Combination therapy for treating cancer |
| DK2836491T3 (en) | 2012-04-13 | 2017-03-06 | Epizyme Inc | SALT FORM OF A HUMAN HISTONMETHYL TRANSFERASE EZH2 INHIBITOR |
| US9562041B2 (en) | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| HUE046790T2 (en) | 2012-10-15 | 2020-03-30 | Epizyme Inc | Methods of treating cancer |
| KR102057365B1 (en) | 2012-10-15 | 2019-12-18 | 에피자임, 인코포레이티드 | Substituted benzene compounds |
| DK2914296T4 (en) * | 2012-11-01 | 2022-01-03 | Infinity Pharmaceuticals Inc | Treatment of cancers using PI3 kinase isoform modulators |
| US20150283142A1 (en) | 2013-03-15 | 2015-10-08 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| US20140120083A1 (en) | 2012-11-01 | 2014-05-01 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| WO2014100080A1 (en) | 2012-12-19 | 2014-06-26 | Glaxosmithkline Llc | Combination |
| US9701666B2 (en) | 2012-12-21 | 2017-07-11 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| CA2894216A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone compounds |
| EP2970306A4 (en) | 2013-03-15 | 2016-08-03 | Epizyme Inc | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2014172044A1 (en) | 2013-03-15 | 2014-10-23 | Epizyme, Inc. | Substituted benzene compounds |
| DK3003309T3 (en) * | 2013-05-30 | 2020-12-14 | Infinity Pharmaceuticals Inc | Treatment of cancer with PI3 kinase isoform modulators |
| WO2015010078A2 (en) | 2013-07-19 | 2015-01-22 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| WO2015010049A1 (en) | 2013-07-19 | 2015-01-22 | Epizyme, Inc. | Substituted benzene compounds |
| CA2923706C (en) | 2013-10-09 | 2020-08-25 | F. Hoffmann-La Roche Ag | Methods and compositions for detecting mutation in the human ezh2 gene |
| FI3057962T3 (en) | 2013-10-16 | 2023-11-03 | Epizyme Inc | Hydrochloride salt form for ezh2 inhibition |
| US20160228447A1 (en) | 2013-10-18 | 2016-08-11 | Epizyme, Inc. | Method of treating cancer |
| CN105873592B (en) | 2013-12-06 | 2023-01-31 | Epizyme股份有限公司 | Combination therapy for the treatment of cancer |
| PT3157527T (en) | 2014-06-17 | 2023-06-30 | Eisai R&D Man Co Ltd | Ezh2 inhibitors for treating lymphoma |
| US20190000860A1 (en) | 2014-11-06 | 2019-01-03 | Dana-Farber Cancer Institute, Inc. | Use of compositions modulating chromatin structure for graft versus host disease (gvhd) |
| IL296080B2 (en) | 2014-11-17 | 2023-12-01 | Eisai R&D Man Co Ltd | Method for treating cancer |
| JP6544507B2 (en) | 2015-02-09 | 2019-07-17 | 日本精機株式会社 | Head-up display device |
| EA201890009A1 (en) | 2015-06-10 | 2018-07-31 | Эпизайм, Инк. | EZH2 INHIBITORS FOR TREATING LYMPHOMA |
| KR20170095656A (en) | 2016-02-15 | 2017-08-23 | 동부대우전자 주식회사 | Washing machine having protection against heat structure |
-
2015
- 2015-06-17 PT PT158095406T patent/PT3157527T/en unknown
- 2015-06-17 CN CN201580036258.XA patent/CN106999498B/en active Active
- 2015-06-17 HU HUE15809540A patent/HUE062158T2/en unknown
- 2015-06-17 CN CN202110532717.0A patent/CN113289022A/en active Pending
- 2015-06-17 EA EA201692285A patent/EA038337B1/en unknown
- 2015-06-17 BR BR112016029492A patent/BR112016029492A2/en not_active Application Discontinuation
- 2015-06-17 EP EP23174369.1A patent/EP4252851A3/en active Pending
- 2015-06-17 US US15/319,535 patent/US10166238B2/en active Active
- 2015-06-17 KR KR1020237004113A patent/KR20230031963A/en not_active Application Discontinuation
- 2015-06-17 CA CA2952074A patent/CA2952074C/en active Active
- 2015-06-17 ES ES15809540T patent/ES2948442T3/en active Active
- 2015-06-17 WO PCT/US2015/036310 patent/WO2015195848A1/en active Application Filing
- 2015-06-17 AU AU2015277139A patent/AU2015277139A1/en not_active Abandoned
- 2015-06-17 IL IL309539A patent/IL309539A/en unknown
- 2015-06-17 KR KR1020177000760A patent/KR102497728B1/en active IP Right Grant
- 2015-06-17 MX MX2016016744A patent/MX2016016744A/en unknown
- 2015-06-17 SI SI201531951T patent/SI3157527T1/en unknown
- 2015-06-17 DK DK15809540.6T patent/DK3157527T3/en active
- 2015-06-17 PL PL15809540.6T patent/PL3157527T3/en unknown
- 2015-06-17 SG SG10201811128RA patent/SG10201811128RA/en unknown
- 2015-06-17 IL IL285201A patent/IL285201B1/en unknown
- 2015-06-17 MX MX2021007651A patent/MX2021007651A/en unknown
- 2015-06-17 LT LTEPPCT/US2015/036310T patent/LT3157527T/en unknown
- 2015-06-17 EP EP15809540.6A patent/EP3157527B1/en active Active
- 2015-06-17 JP JP2016573564A patent/JP6779793B2/en active Active
- 2015-06-17 FI FIEP15809540.6T patent/FI3157527T3/en active
- 2015-06-17 SG SG11201610273VA patent/SG11201610273VA/en unknown
-
2016
- 2016-12-07 IL IL249438A patent/IL249438A0/en unknown
-
2018
- 2018-11-06 US US16/181,747 patent/US20190175604A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/454,835 patent/US20200022987A1/en not_active Abandoned
-
2020
- 2020-03-04 US US16/808,513 patent/US11642347B2/en active Active
- 2020-09-28 AU AU2020244382A patent/AU2020244382B2/en active Active
-
2022
- 2022-11-03 AU AU2022263523A patent/AU2022263523A1/en active Pending
-
2023
- 2023-03-23 US US18/188,716 patent/US20240058348A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201811128RA (en) | Ezh2 inhibitors for treating lymphoma | |
| PH12018500097A1 (en) | Combination of pd-1 antagonist with an egfr inhibitor | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| PH12018500642A1 (en) | Anti-garp antibody | |
| MX2020010535A (en) | Methods of treating cancer. | |
| MX2018005019A (en) | Benzofuran derivative, preparation method thereof and use thereof in medicine. | |
| PH12016502355A1 (en) | Pharmaceutical composition | |
| MX2020010412A (en) | Inhibitors of bruton's tyrosine kinase. | |
| MX2019001125A (en) | Macrocycle kinase inhibitors. | |
| TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
| MX2016008201A (en) | Cancer treatment using combinations of erk and raf inhibitors. | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| JO3784B1 (en) | Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer | |
| MX2017015574A (en) | Inhibitors of bruton's tyrosine kinase. | |
| PH12016502291A1 (en) | Indolizine derivatives as phosphoinositide 3-kinases inhibitors | |
| MX2017004618A (en) | Heparan sulfate biosynthesis inhibitors for the treatment of diseases. | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| TW201613578A (en) | Pharmaceutical combinations | |
| MA39765A (en) | Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use | |
| MX2017013137A (en) | Chromene derivatives as phoshoinositide 3-kinases inhibitors. | |
| MX2016003522A (en) | Quinazoline derivatives and their use as dna methyltransferase inhibitors. | |
| MX2017011018A (en) | Inhibition of olig2 activity. | |
| MX2019001467A (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer. | |
| ZA201901367B (en) | Inhibition of olig2 activity | |
| EP3991749A3 (en) | A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody |